The 5 Thinnest States in America
Only five states had residents with Body Mass Index (BMI) at or below the range considered normal, according to CDC research.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 215
Can Shares of Aeglea BioTherapeutics Really More Than Double?
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) has only been public for a few weeks, but the analysts from its underwriting syndicate have issued massive upside calls. The driving force behind Aeglea is that the biotechnology…
What to Expect From Pfizer Earnings
Pfizer is scheduled to report its first-quarter financial results before the markets open on Tuesday.
Analysts Make Major Changes to Top Biotech Ratings
With earnings having just been released for some of the top biotech companies, we saw a flurry of analyst calls by the week's end.
How Analysts View Vertex After Earnings
One portfolio manager on CNBC noted that Vertex could end up being an acquisition target ahead, without mentioning any specifics.
Did Molina Healthcare’s Future Just Get Compromised?
Molina Healthcare to a real beating after reporting a bad miss on first-quarter earnings. The stock was down nearly 20% on Friday.
How Analysts View Stericycle After Earnings
Stericycle first-quarter financial results missed earnings expectations and the stock saw a new 52-week low early in Friday's session.
Gilead Results Trip Over Both the Top and Bottom Lines
Gilead Sciences Inc. (NASDAQ: GILD) reported first-quarter financial results after the markets closed on Thursday. The company had $3.03 in earnings per share (EPS) on $7.79 billion in revenue compared to consensus estimates from…
Bristol-Myers Squibb Offers Up Solid Earnings Beat and Lifts Guidance
Bristol-Myers Squibb released better-than-expected first-quarter financial results before the markets opened on Thursday.
Why AbbVie Earnings Failed to Impress Investors
AbbVie reported its first-quarter financial results and guidance before the markets opened on Thursday.
Spring Bank Pharmaceuticals Scales Back IPO
Spring Bank Pharmaceuticals expects to price more than a million shares in the range of $12 to $14 per share in an initial public offering valued up to more than $18 million.
Major Pharma Short Interest Remains Mixed, With 1 Massive Drop
The April 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest was mixed.
Short Sellers Run for Cover From Major Biotechs
The April 15 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Why Global Pharma Profits Should Keep Rising
If Moody's is correct, pharmaceutical earnings will keep growing for at least the next year and a half.
Why This Isn’t the End of Catalyst Pharmaceuticals
Catalyst Pharmaceuticals saw its shares get halved just Tuesday morning alone, following a business update regarding its Lambert-Eaton myasthenic syndrome treatment.